Spero Therapeutics, Inc.

Spero Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Spero Therapeutics, Inc. has 58.15M shares outstanding.

As of June 30, 2026, Spero Therapeutics, Inc. maintains a current ratio of 6.12, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Spero Therapeutics, Inc. posted a return on equity (ROE) of 19.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.86, useful for judging operating efficiency across full business cycles. The company generates approximately 28.06M in revenue per employee across its workforce of 26.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Spero Therapeutics, Inc. recorded 4.56M in income tax expense. That works out to an effective tax rate of 3.41, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 133.55M, leaving 128.99M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Spero Therapeutics, Inc. generated 750.65M in revenue and converted that into 128.99M in net income, yielding earnings per share of 2.23. EBITDA reached 105.27M, while operating income came in at 115.52M.

As of June 30, 2026, Spero Therapeutics, Inc. holds 887.10M in cash and equivalents against 35.69M in total debt, resulting in a net debt position of -887.10M. Total book value stands at 772.31M, with working capital of 754.00M providing operational flexibility.

Spero Therapeutics, Inc. produced 342.09M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of 15.39 and net profit margin of 17.18 provide insight into operational efficiency.